Here are three highlights:
1. The new products, MarBrane, MarGraft and MarCell are anticipated to significantly accelerate the company’s top line revenue growth.
2. MarBrane and MarGraft are expected to launch in second quarter of 2016. MarCell is expected to launch in the third quarter of 2016.
3. Based in Scottsdale, Ariz., Lattice Biologics develops and manufactures biologic products used in a variety of applications, such as spine surgery, orthopedics and sports medicine, among others.
More articles on devices and implants:
Bone Biologics completes $5M+ financing round: 3 things to know
RTI Surgical launches laminoplasty fixation system: 4 key notes
Pinnacle Spine Group receives Chinese patent for spinal fusion technology: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
